期刊文献+

重症肌无力最新治疗进展 被引量:11

下载PDF
导出
摘要 重症肌无力(myasthenia gravis,MG)的治疗目的是根据临床表现和亚型进行个体化治疗,以尽快恢复患者功能,并尽量减少不良反应。MG的治疗,包括改善症状的胆碱酯酶抑制剂,糖皮质激素(以下简称“激素”)、硫唑嘌呤、霉酚酸酯(mycophenolate mofetil,MMF)、环孢素、他克莫司(FK506)等免疫抑制剂,用于难治性MG的环磷酰胺(CTX)、利妥昔单抗,
出处 《中国神经免疫学和神经病学杂志》 CAS 2010年第6期457-459,共3页 Chinese Journal of Neuroimmunology and Neurology
  • 相关文献

参考文献8

  • 1Zisimopoulou P,Lagoumintzis G,Kostelidou K,et al.Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis[J].J Neuroimmunol,2008,201-202:95-103.
  • 2Sanders DB,Hart IK,Mantegazza R,et al.An international,phase Ⅲ,randomized trial of mycophenolate mofetil in myasthenia gravis[J].Neurology,2008,71:400-406.
  • 3Drachman DB,Adams RN,Hu R,et al.Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis[J].Ann N Y Acad Sci,2008,1132:305-314.
  • 4Tandan R,Potter C,Bradshaw DY.Pilot trial of rituximab in myasthenia gravis[J].Neurology,2008,70 (suppl 1):A301.
  • 5Argov Z,McKee D,Agus S,et al.Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase[J].Neurology,2007,69:699-700.
  • 6Zhou Y,Gong B,Lin F,et al.Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis[J].J Immunol,2007,179(12):8562-8567.
  • 7Sheng JR,Li L,Ganesh BB,et al.Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia[J].Clin Immunol,2008,128:172-180.
  • 8Matsushita T,Yanaba K,Bouaziz JD,et al.Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression[J].J Clin Invest,2008,118(10):3420-3430.

同被引文献68

引证文献11

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部